Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Temozolomide in Pediatric Solid Tumors
NCT02689336Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2016
- Primary completion
- Nov 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of erlotinib in glioma, rhabdomyosarcoma (RMS), osteosarcoma (OS), medulloblastoma, neuroectodermal tumor, sponsored by Washington University School of Medicine. Planned start Aug 2016; status: withdrawn.
02
Drugs
erlotinib
03
Conditions
gliomarhabdomyosarcoma (RMS)osteosarcoma (OS)medulloblastomaneuroectodermal tumor
Beyond the preview
Go deeper on NCT02689336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689336.